Stay updated on Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Sign up to get notified when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.

Latest updates to the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference1%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1.0%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check66 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check81 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical study of nab-sirolimus for solid tumors, including detailed eligibility criteria and study procedures. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference43%
Stay in the know with updates to Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.